INmune Bio, Inc.: INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in ...
Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio ...
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development ...
REDWOOD CITY, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development ...